Six-minute walk test in managing and monitoring sarcoidosis patients

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 439-444

  Baughman, Robert P ^a,b   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

6 min walk test; Exercise; Fatigue; Pulmonary hypertension

Indexed keywords

BOSENTAN; ETANERCEPT; INFLIXIMAB; METHYLPHENIDATE; PROSTACYCLIN;

CORRELATION ANALYSIS; DYSPNEA; FATIGUE; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CONGESTION; LUNG FUNCTION; MUSCLE CONTRACTION; MUSCLE STRENGTH; PATIENT ASSESSMENT; PATIENT MONITORING; PULMONARY HYPERTENSION; REVIEW; SARCOIDOSIS; SKELETAL MUSCLE; SOCIAL PSYCHOLOGY; SYMPTOM; THORAX RADIOGRAPHY; WALKING;

DYSPNEA; EXERCISE TEST; HUMANS; PROGNOSIS; SARCOIDOSIS, PULMONARY; TIME FACTORS; TRAUMA SEVERITY INDICES; WALKING;

EID: 34748856265     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328273bc2b     Document Type: Review

References (64)

1. Baughman RP, Teirstein AS, Judson MA, et al., A Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-1889.
2. Mascolo MC, Truwit JD. Role of exercise evaluation in restrictive lung disease: new insights between March 2001 and February 2003. Curr Opin Pulm Med 2003; 9:408-410.
3. Akkoca O, Celik G, Ulger F, et al. Exercise capacity in sarcoidosis: study of 29 patients. Med Clin (Barc) 2005; 124:686-689.
4. Delobbe A, Perrault H, Maitre J, et al. Impaired exercise response in sarcoid patients with normal pulmonary function. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:148-153.
5. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. Chest 2001; 120:93-101.
6. Karetzky M, McDonough M. Exercise and resting pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:43-49.
7. Sharma OP, Johnson R. Airway obstruction in sarcoidosis: a study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988; 94:343-346.
8. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-1123.
9. Chetta A, Aiello M, Foresi A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:170-175.
10. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997; 16:313-319.
11. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659-664. Examining a large cohort of 454 IPF patients provides support of previous references showing the value of using 6MWD in predicting survival for IPF patients awaiting lung transplant. No data are provided on other interstitial lung diseases.
12. Sciurba F, Criner GJ, Lee SM, et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003; 167:1522-1527.
13. Medical Research Council. Committee on research on chronic bronchitis: instructions for use of the questionnaire on respiratory symptoms. Devon, UK: W.J. Holdman; 1966.
14. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758.
15. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1:165-172.
16. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381.
17. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:147-153.
18. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163:329-334.
19. Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125:997-1004.
20. Drent M, Wirnsberger RM, Breteler MH, et al. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:59-66.
21. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116:1175-1182.
22. Cox CE, Donohue JF, Brown CD, et al. The sarcoidosis health questionnaire: a new measure of health-related quality of life. Am J Resp Crit Care Med 2003; 168:323-329.
23. Michielsen HJ, Peros-Golubicic T, Drent M, de Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2006; 7 April [Epub ahead of print]. A comparison of the various measures of quality of life with symptoms in a large group of sarcoidosis patients.
24. de Vries J, Rothkrantz-Kos S, Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:127-136.
25. Baughman RP, Sparkman BK, Lower EE. Six minute walk test and health status assessment in sarcoidosis. Chest (in press).
26. Lai JS, Cella D, Chang CH, et al. Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 2003; 12:485-501.
27. de Vries J, Michielsen H, van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9:279-291.
28. de Vries J, Rothkrantz-Kos S, Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:127-136.
29. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29-35.
30. Fouchier SM, Moller GM, Van Santen-Hoeufft M, et al. [Successful treatment with infliximab of a patient with refractory sarcoidosis]. Ned Tijdschr Geneeskd 2004; 148: 2446-2450.
31. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006; 14:210-215.
32. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21:4439-4443.
33. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:235.
34. Jamal MM, CiLursu AH, Hoffman EL. Sarcoidosis presenting as acute myositis: report and review of literature. J Rheumatol 1988; 15:1868-1878.
35. Ost D, Yeldandi A, Cugell D. Acute sarcoid myositis with respiratory muscle involvement: case report and review of the literature. Chest 1995; 107:879-882.
36. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:219-227.
37. Kabitz HJ, Lang F, Walterspacher S, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130:1496-1502. The authors found significantly reduced inspiratory muscle strength in three of 18 unselected sarcoidosis patients. Those patients had a reduction in their 6MWD.
38. Criner G, Cordova FC, Leyenson V, et al. Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit Care Med 1998; 157:1578-1585.
39. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32-38.
40. Sietsema KE, Kraft M, Ginzton L, Sharma OP. Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. Chest 1992; 102:838-845.
41. Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 1992; 68 (Suppl 1):S52-S56.
42. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109:62-66.
43. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129:1246-1252. A prospective study looking for pulmonary hypertension in an unselected group of Japanese sarcoidosis patients. The limitations of the study are that the authors used only echo to screen and that pulmonary disease was fairly mild in the patients studied. This study, however, provides a minimum percentage of pulmonary hypertension in sarcoidosis.
44. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (in press).
45. Rizzato G, Pezzano A, Sala G, et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64:121-128.
46. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128:1483-1489.
47. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120:866-872.
48. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481-1488. Study demonstrating that pulmonary arterial hypertension in sarcoidosis can be successfully treated with epoprostenol. Not only was there an improvement in 6MWD, but also prolonged survival in some patients.
49. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with Bosentan. Respiration 2005; 15 November [Epub ahead of print].
50. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.
51. Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med 2004; 25:435-453.
52. Lettieri CJ, Nathan SD, Browning RF, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 2006; 100:1734-1741. The authors combined the results of the 6MWD with the lowest oxygen saturation. This product was a better predictor of mortality than either feature alone. Reproducibility, however, is not discussed.
53. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:1150-1157.
54. Leach RM, Davidson AC, Chinn S, et al. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992; 47:781-789.
55. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084-1090.
56. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174:803-809. A drop in 6MWD over time was more predictive of increased mortality than the initial value in IPF patients.
57. Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25:96-103.
58. Stevens D, Elpern E, Sharma K, et al. Comparison of hallway and treadmill six-minute walk tests. Am J Respir Crit Care Med 1999; 160:1540-1543.
59. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-1047.
60. Dal Corso S, Duarte SR, Neder JA, et al. A step test to assess exercise-related oxygen desaturation in interstitial lung disease. Eur Respir J 2007; 29:330-336. Another measure of walking ability, using a simple step test. The major advantage was that it detected desaturation in a shorter period and with less space requirements. The test, however, has not been compared with other outcomes such as mortality.
61. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000; 109:207-212.
62. Niederman MS, Clemente PH, Fein AM, et al. Benefits of a multidisciplinary pulmonary rehabilitation program: improvements are independent of lung function. Chest 1991; 99:798-804.
63. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823-832.
64. Miyahara N, Eda R, Takeyama H, et al. Effects of short-term pulmonary rehabilitation on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease. Acta Med Okayama 2000; 54:179-184.